Key statistics
As of last trade Arcutis Biotherapeutics Inc (ARQT:NSQ) traded at 10.19, -22.63% below its 52-week high of 13.17, set on Apr 09, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 10.23 |
---|---|
High | 10.37 |
Low | 10.05 |
Bid | 10.16 |
Offer | 10.19 |
Previous close | 10.24 |
Average volume | 1.95m |
---|---|
Shares outstanding | 117.04m |
Free float | 114.53m |
P/E (TTM) | -- |
Market cap | 1.20bn USD |
EPS (TTM) | -1.79 USD |
Data delayed at least 15 minutes, as of Nov 22 2024 15:34 GMT.
More ▼
- Arcutis’ ZORYVE® (roflumilast) Awarded Best Eczema Treatment by Glamour
- Arcutis Announces Third Quarter 2024 Financial Results and Provides Business Update
- Arcutis Presents Positive Patient-Reported Outcome Data for ZORYVE® (Roflumilast) Cream 0.15% in Atopic Dermatitis at American College of Allergy, Asthma and Immunology 2024 Annual Scientific Meeting
- Arcutis Announces Health Canada Approval of ZORYVE® (Roflumilast) Foam 0.3% to Treat Seborrheic Dermatitis in Individuals 9 Years of Age and Older
- New Data Shows ZORYVE® (Roflumilast) Cream 0.15% Provided Consistent Improvement of Atopic Dermatitis in Individuals With Diverse Skin Types
- FDA Accepts Arcutis’ Supplemental New Drug Application for ZORYVE® (roflumilast) Foam for the Treatment of Scalp and Body Psoriasis in Adults and Adolescents Ages 12 and Over
- Arcutis Announces Publication of ZORYVE® (roflumilast) Cream 0.15% Pivotal Results from Phase 3 INTEGUMENT-1 and -2 Trials in Mild to Moderate Atopic Dermatitis in Journal of American Medical Association Dermatology
- Arcutis Completes Enrollment of Phase 1b Alopecia Areata Study Evaluating ARQ-255
- Arcutis Announces Positive Long-Term Results of Roflumilast Cream 0.05% Show Durable and Improved Efficacy Over Time and Favorable Safety Profile in Treatment of Children Aged 2 to 5 with Mild to Moderate Atopic Dermatitis
- CORRECTION – Arcutis Announces Second Quarter 2024 Financial Results and Provides Business Update
More ▼